ArticleBMC nephrology2026
Association between S100 calcium-binding protein A12 and sepsis associated-acute kidney injury: a prospective cohort study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-associated acute kidney injury (SA-AKI) is a common and severe complication in critically ill patients, yet early diagnostic biomarkers remain limited. S100A12, a pro-inflammatory calcium-binding protein, may contribute to sepsis-induced renal injury through oxidative and immune-mediated mechanisms. This study aimed to investigate the association between plasma S100A12 levels and the risk of SA-AKI in a prospective sepsis cohort.
methodsIn this prospective cohort study, 202 adult patients with sepsis were consecutively enrolled. Plasma S100A12 levels were measured at enrollment. Associations between S100A12 (continuous and tertiles) and SA-AKI were assessed using multivariable logistic regression (Models 1–3) with progressive adjustment for clinical and laboratory covariates. Restricted cubic spline (RCS) regression and Cox proportional-hazards models were applied to evaluate dose–response and temporal relationships. Predictive performance was assessed using receiver-operating characteristic (ROC) analysis.
resultsSA-AKI occurred in 59.9% of participants. S100A12 concentrations were positively associated with SA-AKI risk. After adjustment for confounders, elevated S100A12 was independently associated with SA-AKI (odds ratio 1.17, 95% CI 1.11–1.24, p < 0.001). No significant interactions were observed across predefined subgroups (all p for interaction > 0.05). The area under the ROC curve (AUC) was 0.839 (95% CI 0.783–0.895).
conclusionsHigher plasma S100A12 levels were independently associated with the development of sepsis-associated acute kidney injury in critically ill patients with sepsis. S100A12 may represent a candidate biomarker for early risk stratification in SA-AKI; however, external validation in larger, multicenter cohorts is required before any potential clinical application.
trial registrationThis prospective observational study was retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR2400094790) on December 27, 2024, after ethics approval, as no interventional procedures were performed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.